Subjective cognitive decline (SCD), considered a preclinical dementia stage, is less understood in Hispanics, a high-risk group for dementia. We investigated SCD to mild cognitive impairment (MCI) progression risk, as well as baseline and longitudinal features of depressive symptoms, SCD complaints, and objective cognitive performance among Hispanics compared to non-Hispanic Whites (NHW).
Methods
Hispanic (n = 23) and NHW (n = 165) SCD participants were evaluated at baseline and 2-year follow-up. Evaluations assessed function, depressive symptoms, SCD, and objective cognitive performance.
Results
Hispanics were at increased risk of progression to MCI (OR: 6.10, 95% CI 1.09-34.20, P = .040). Hispanic participants endorsed more depressive symptoms at baseline (P = .048) that worsened more longitudinally (OR: 3.16, 95% CI 1.18-8.51, P = .023). Hispanic participants had increased SCD complaints on the Brief Cognitive Rating Scale (BCRS) (β = .40 SE: .17, P = .023), and in specific BCRS domains: concentration (β = .13, SE: .07, P = .047), past memory (β = .13, SE: .06, P = .039) and functional abilities (β = .10, SE: .05, P = .037). In objective cognitive performance, Hispanic ethnicity associated with decline in MMSE (β = −.27, SE: .13, P = .039), MoCA (β = −.80 SE: .34, P = .032), Trails A (β = 2.75, SE: .89, P = .002), Trails B (β = 9.18, SE: 2.71, P = .001) and Guild Paragraph Recall Delayed (β = −.80 SE: .28, P = .005). Conclusions: Hispanic ethnicity associated with a significantly increased risk of 2-year progression of SCD to MCI compared to NHW. This increased risk associated with increased depressive symptoms, distinctive SCD features, and elevated amnestic and non-amnestic objective cognitive decline. This supports further research to refine the assessment of preclinical dementia in this high-risk group.
Lewis-FernándezRDasAKAlfonsoCWeissmanMMOlfsonM. Depression in US Hispanics: diagnostic and management considerations in family practice. J Am Board Fam Pract. 2005;18(4):282-296. doi:10.3122/jabfm.18.4.282.
2.
ManlyJJMayeuxR. In: AndersonNBBulataoRACohenB, eds. Critical Perspectives on Racial and Ethnic Differences in Health in Late Life. Washington, D.C: National Academies Press, 2004.
3.
VillaVMWallaceSPBagdasaryanSArandaMP. Hispanic Baby Boomers: health inequities likely to persist in old age. Gerontol. 2012;52(2):166-176. doi:10.1093/geront/gns002.
4.
Velasco-MondragonEJimenezAPalladino-DavisAGDavisDEscamilla-CejudoJA. Hispanic health in the USA: a scoping review of the literature. Publ Health Rev. 2016;37:31. doi:10.1186/s40985-016-0043-2.
5.
ManlyJJTangMXSchupfNSternYVonsattelJPGMayeuxR. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63(4):494-506. doi:10.1002/ana.21326.
6.
GurlandBJWilderDELantiguaR, et al.Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatr. 1999;14(6):481-493.
7.
Samper-TernentRKuoYFRayLAOttenbacherKJMarkidesKSAl SnihS. Prevalence of health conditions and predictors of mortality in oldest old Mexican Americans and non-Hispanic whites. J Am Med Dir Assoc. 2012;13(3):254-259. doi:10.1016/j.jamda.2010.07.010.
FittenLJOrtizFPontónM. Frequency of Alzheimer’s disease and other dementias in a community outreach sample of Hispanics. J Am Geriatr Soc. 2001;49(10):1301-1308. doi:10.1046/j.1532-5415.2001.49257.x.
10.
LinPJDalyATOlchanskiN, et al.Dementia diagnosis disparities by race and ethnicity. Med Care. 2021;59(8):679-686. doi:10.1097/MLR.0000000000001577.
11.
ZlatarZZTarrafWGonzálezKA, et al.Subjective cognitive decline and objective cognition among diverse U.S. Hispanics/latinos: results from the study of latinos-investigation of neurocognitive aging (SOL-INCA). Alzheimers Dement. 2022;18(1):43-52. doi:10.1002/alz.12381.
12.
NakhlaMZCohenLSalmonDP, et al.Self-reported subjective cognitive decline is associated with global cognition in a community sample of Latinos/as/x living in the United States. J Clin Exp Neuropsychol. 2021;43(7):663-676. doi:10.1080/13803395.2021.1989381.
13.
Guerrero-BerroaEKlugerASchmeidlerJ, et al.Neuropsychological and neuropsychiatric prediction of global cognitive status among older Spanish-speaking Hispanics and English-speaking whites. J Geriatr Psychiatr Neurol. 2014;27(4):266-275. doi:10.1177/0891988714532020.
14.
AmariglioREMorminoECPietrasAC, et al.Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly. Neurology. 2015;85(1):56-62. doi:10.1212/WNL.0000000000001712.
15.
MolinuevoJLRabinLAAmariglioR, et al.Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296-311. doi:10.1016/j.jalz.2016.09.012.
16.
JessenFAmariglioREvan BoxtelM, et al.A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001.
17.
RabinLASmartCMAmariglioRE. Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13:369-396. doi:10.1146/annurev-clinpsy-032816-045136.
18.
RabinLASmartCMCranePK, et al.Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. J Alzheimers Dis. 2015;48 (Suppl 1):S63-86. doi:10.3233/JAD-150154.
19.
ReisbergBShulmanMBTorossianCLengLZhuW. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11-24. doi:10.1016/j.jalz.2009.10.002.
20.
HampelHListaSKhachaturianZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 2012;8(4):312-336. doi:10.1016/j.jalz.2012.05.2116.
21.
JackCRBennettDABlennowK, et al.NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018.
22.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003.
23.
ReisbergBTorossianCShulmanMB, et al.Two year outcomes, cognitive and behavioral markers of decline in healthy, cognitively normal older persons with global deterioration Scale stage 2 (subjective cognitive decline with impairment). J Alzheimers Dis. 2019;67(2):685-705. doi:10.3233/JAD-180341.
24.
TaylorCABouldinEDMcGuireLC. Subjective cognitive decline among adults aged ≥45 Years - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67(27):753-757. doi:10.15585/mmwr.mm6727a1.
25.
SlotRERSikkesSAMBerkhofJ, et al.Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement. 2019;15(3):465-476. doi:10.1016/j.jalz.2018.10.003.
26.
VosSJXiongCVisserPJ, et al.Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965. doi:10.1016/S1474-4422(13)70194-7.
27.
GarciaMAWarnerDFGarcíaCDownerBRajiM. Age patterns in self-reported cognitive impairment among older Latino subgroups and non-latino whites in the United States, 1997-2018: implications for public health policy. Innov Aging. 2021;5(4):igab039. doi:10.1093/geroni/igab039.
28.
GuptaS. Racial and ethnic disparities in subjective cognitive decline: a closer look, United States, 2015-2018. BMC Publ Health. 2021;21(1):1173. doi:10.1186/s12889-021-11068-1.
29.
ZlatarZZMunizMCEspinozaSG, et al.Subjective cognitive decline, objective cognition, and depression in older Hispanics screened for memory impairment. J Alzheimers Dis. 2018;63(3):949-956. doi:10.3233/JAD-170865.
30.
BabulalGMQuirozYTAlbensiBC, et al.Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: update and areas of immediate need. Alzheimers Dement. 2019;15(2):292-312. doi:10.1016/j.jalz.2018.09.009.
31.
HallJRWiechmannAJohnsonLAEdwardsMO’BryantSE. Characteristics of cognitively normal Mexican-Americans with cognitive complaints. J Alzheimers Dis. 2018;61(4):1485-1492. doi:10.3233/JAD-170836.
32.
AmariglioREDonohueMCMarshallGA, et al.Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer’s Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015;72(4):446-454. doi:10.1001/jamaneurol.2014.3375.
33.
DuboisBHampelHFeldmanHH, et al.Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer's Dementia. 2016;12(3):292-323. doi:10.1016/j.jalz.2016.02.002.
34.
SperlingRAJackCRAisenPS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111). doi:10.1126/scitranslmed.3002609.
35.
Fernández-BlázquezMAÁvila-VillanuevaMMaestúFMedinaM. Specific features of subjective cognitive decline predict faster conversion to mild cognitive impairment. J Alzheimers Dis. 2016;52(1):271-281. doi:10.3233/JAD-150956.
36.
ReisbergBFerrisSHde LeonMJCrookT. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatr. 1982;139(9):1136-1139. doi:10.1176/ajp.139.9.1136.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6.
41.
WeintraubSSalmonDMercaldoN, et al.The Alzheimer’s disease centers’ uniform data Set (UDS). Alzheimer Dis Assoc Disord. 2009;23(2):91-101. doi:10.1097/WAD.0b013e318191c7dd.
42.
CrookTGilbertJGFerrisS. Operationalizing memory impairment for elderly persons: the Guild Memory Test. Psychol Rep. 1980;47(3 Pt 2):1315-1318. doi:10.2466/pr0.1980.47.3f.1315.
43.
ChapmanSRenteríaMADworkinJD, et al.Association of subjective cognitive decline with progression to dementia in a cognitively unimpaired multiracial community sample. Neurology. 2023;100(10). doi:10.1212/WNL.0000000000201658.
44.
JormAFChristensenHKortenAEJacombPAHendersonAS. Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7-8 years. Psychol Med. 2001;31(3):441-449.
45.
VogelAStokholmJGadeAAndersenBBHejlAMWaldemarG. Awareness of deficits in mild cognitive impairment and Alzheimer’s disease: do MCI patients have impaired insight?Dement Geriatr Cogn Disord. 2004;17(3):181-187. doi:10.1159/000076354.
46.
BurkeSLRodriguezMJBarkerW, et al.Relationship between cognitive performance and measures of neurodegeneration among hispanic and white non-hispanic individuals with normal cognition, mild cognitive impairment, and dementia. J Int Neuropsychol Soc. 2018;24(2):176-187. doi:10.1017/S1355617717000820.
47.
WilkinsCHWindonCCDilworth-AndersonP, et al.Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia. JAMA Neurol. 2022;79(11):1139. doi:10.1001/jamaneurol.2022.3157.
48.
O’BryantSEJohnsonLABarberRC, et al.The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimers Dement (Amst). 2021;13(1): e12202. doi:10.1002/dad2.12202.
49.
O’BryantSEZhangFPetersenM, et al.Neurodegeneration from the at(N) framework is different among Mexican Americans compared to non‐hispanic whites: a health & aging brain among Latino elders (hable) study. Alzheimers Dement (Amst). 2022;14(1): e12267. doi:10.1002/dad2.12267.
50.
QuirozYTSolisMArandaMP, et al.Addressing the disparities in dementia risk, early detection and care in Latino populations: highlights from the second Latinos & Alzheimer’s Symposium. Alzheimers Dement. 2022;18(9):1677-1686. doi:10.1002/alz.12589.
51.
RothsteinAZhangYBriggsAQ, et al.Impact of white matter hyperintensities on subjective cognitive decline phenotype in a diverse cohort of cognitively normal older adults. Int J Geriatr Psychiatr. 2023;38(6):e5948. doi:10.1002/gps.5948.
52.
RizziLMissiaggiaLRoriz-CruzM. CSF aβ1-42, but not p-tau181, predicted progression from amnestic MCI to Alzheimer’s disease dementia. NeuroMolecular Med. 2018;20(4):491-497. doi:10.1007/s12017-018-8516-8.
53.
QuYMaYHHuangYY, et al.Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;128:479-486. doi:10.1016/j.neubiorev.2021.07.007.
54.
SmirnovDSAshtonNJBlennowK, et al.Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143(4):487-503. doi:10.1007/s00401-022-02408-5.
55.
RaoRVSubramaniamKGGregoryJ, et al.Rationale for a multi-factorial approach for the reversal of cognitive decline in Alzheimer’s disease and MCI: a review. Int J Mol Sci. 2023;24(2):1659. doi:10.3390/ijms24021659.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
